Versartis chief development officer to leave
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Versartis Inc. said Chief Development Officer Colin Hislop's employment will be terminated, effective Oct. 20.
Hislop joined Versartis in 2016 from Anthera Pharmaceuticals Inc., where he served as the company's chief medical officer.
